Lianne S. Gensler
YOU?
Author Swipe
View article: Association between MRI findings and inflammatory symptoms in non-specific chronic low back pain
Association between MRI findings and inflammatory symptoms in non-specific chronic low back pain Open
View article: Dr. Gensler et al reply
Dr. Gensler et al reply Open
View article: ASAS recommendations on reporting axial spondyloarthritis clinical trials
ASAS recommendations on reporting axial spondyloarthritis clinical trials Open
These ASAS-endorsed recommendations on axSpA clinical trial reporting provide a standardised approach to reporting both baseline features as well as outcomes from axSpA clinical trials.
View article: Real‐World Use of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations
Real‐World Use of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations Open
Objective The objective of this study was to evaluate 12‐month persistence of biologic and targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) treatment in US patients with axial spondyloarthritis (axSpA) using real‐world d…
View article: Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2B/3 Trials
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2B/3 Trials Open
Objectives Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL17A. Here, we report long-term incidence of acute anterior uveitis (uveitis’) following BKZ treatment in patients (p…
View article: Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets Open
Objective To evaluate the performance of machine learning (ML) models for the automated scoring of spinal MRI bone marrow oedema (BMO) in patients with axial spondyloarthritis (axSpA) and compare them with expert scoring. Methods ML algori…
View article: POS0893 EFFICACY OF SECUKINUMAB ACROSS THE AXIAL SPONDYLOARTHRITIS SPECTRUM AMONG PATIENTS GROUPED BY AGE (≥40 YEARS VS <40): A POST HOC ANALYSIS OF 6 PHASE 3 TRIALS
POS0893 EFFICACY OF SECUKINUMAB ACROSS THE AXIAL SPONDYLOARTHRITIS SPECTRUM AMONG PATIENTS GROUPED BY AGE (≥40 YEARS VS <40): A POST HOC ANALYSIS OF 6 PHASE 3 TRIALS Open
View article: POS0920 BIMEKIZUMAB DEMONSTRATES COMPARABLE ONE-YEAR EFFICACY IN MALE AND FEMALE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
POS0920 BIMEKIZUMAB DEMONSTRATES COMPARABLE ONE-YEAR EFFICACY IN MALE AND FEMALE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES Open
View article: POS0256 NONSTEROIDAL ANTI-INFLAMMATORY DRUG USE AND INCIDENT HYPERTENSION AMONG PATIENTS WITH AXIAL SPONDYLOARTHRITIS: INSIGHTS FROM THE DESIR COHORT
POS0256 NONSTEROIDAL ANTI-INFLAMMATORY DRUG USE AND INCIDENT HYPERTENSION AMONG PATIENTS WITH AXIAL SPONDYLOARTHRITIS: INSIGHTS FROM THE DESIR COHORT Open
View article: ABS0706 SUSTAINABILITY OF CLINICAL RESPONSE THROUGH 2 YEARS AMONG UPADACITINIB-TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS: DATA FROM THE SELECT-AXIS 1 AND SELECT-AXIS 2 TRIALS
ABS0706 SUSTAINABILITY OF CLINICAL RESPONSE THROUGH 2 YEARS AMONG UPADACITINIB-TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS: DATA FROM THE SELECT-AXIS 1 AND SELECT-AXIS 2 TRIALS Open
View article: POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION
POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION Open
View article: Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies Open
Objective To assess the long-term safety profile of bimekizumab (BKZ) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Methods Safety data pooled from six integrated phase IIb/III studies in axSpA and PsA are…
View article: P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies
P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies Open
Background/Aims Updated pooled safety data are presented to July 2023, across integrated phase 2b/3 studies of bimekizumab (BKZ) in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients. Methods Safety data are reported fo…
View article: Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis
Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis Open
Objective We aimed to assess differences in baseline characteristics, efficacy, and safety of advanced therapies between male and female patients with axial spondyloarthritis (axSpA) in randomized controlled trials (RCTs). Methods We condu…
View article: The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis Open
View article: Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies Open
Objectives Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axia…
View article: Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension Open
Objective Assess long-term safety, tolerability and efficacy of bimekizumab in ankylosing spondylitis (radiographic axial spondyloarthritis (r-axSpA)). Methods Patients with active r-axSpA completing the dose-ranging 48-week randomised con…
View article: Associations of sociodemographic, clinical factors and HLA-B alleles with enthesitis and peripheral arthritis in patients with ankylosing spondylitis
Associations of sociodemographic, clinical factors and HLA-B alleles with enthesitis and peripheral arthritis in patients with ankylosing spondylitis Open
Objectives Factors associated with peripheral arthritis and enthesitis, especially Achilles tendonitis and plantar fasciitis, were examined in a longitudinal cohort of 1075 patients with ankylosing spondylitis (AS) (also known as radiograp…
View article: Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis) Commencing Late in Life
Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis) Commencing Late in Life Open
View article: Prologue: Spondyloarthritis Unmet Research Needs Conference IV
Prologue: Spondyloarthritis Unmet Research Needs Conference IV Open
The Spondylitis Association of America (SAA) and the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) convened a conference on the campus of the National Institutes of Health (NIH) on September 28 and 29, 2023, to…
View article: Unmet Needs in Spondyloarthritis: Imaging in Axial Spondyloarthritis
Unmet Needs in Spondyloarthritis: Imaging in Axial Spondyloarthritis Open
Imaging biomarkers in axial spondyloarthritis (axSpA) are currently the most specific biomarkers for the diagnosis of this condition. Despite advances in imaging, from plain radiographs—which detect only damage—to magnetic resonance imagin…
View article: The mSQUASH is a feasible and valid measurement tool to uniformly assess daily physical activity in patients with rheumatic diseases
The mSQUASH is a feasible and valid measurement tool to uniformly assess daily physical activity in patients with rheumatic diseases Open
Background The modified Short QUestionnaire to ASsess Health-enhancing physical activity (mSQUASH) was originally developed and validated in Dutch patients with axial spondyloarthritis (axSpA). To support world-wide distribution, applicabi…
View article: A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment Open
Objective To investigate the clinical response at week 52 in patients with AS who received secukinumab 300 vs 150 mg after inadequate response to 150 mg at week 16. Methods ASLeap (NCT03350815) was a randomized, double-blind, parallel-grou…
View article: Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports
Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports Open
As the data are limited for in utero exposure to upadacitinib, definitive conclusions cannot be drawn regarding the effect of upadacitinib on pregnancy outcomes. Rates of adverse pregnancy outcomes with upadacitinib exposure were comparabl…
View article: Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials Open
View article: Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies Open
Objective To assess the impact of bimekizumab on physical functioning, sleep, work productivity and overall health-related quality of life (HRQoL) in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA…
View article: Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials Open
Objective This post hoc analysis assessed the effect of baseline C-reactive protein (CRP) on the efficacy and safety of tofacitinib (TOF) use in ankylosing spondylitis (AS), as well as patient-reported outcomes (PROs). Methods Phase II ( C…
View article: Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status Open
Objective There is a paucity of data on long-term clinical responses in patients with non-radiographic axial spondyloarthritis (nr-axSpA) based on their baseline objective signs of inflammation such as MRI or C-reactive protein (CRP) level…
View article: Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials Open
View article: P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials Open
Background/Aims Acute anterior uveitis (‘uveitis’) is a common extra musculoskeletal manifestation of axial spondyloarthritis (axSpA). Interleukin (IL)-17 has been implicated in uveitis pathogenesis; however, inhibition of IL-17A alone may…